Scientists get first-ever glimpse of 'teenage' HIV-neutralizing antibody

April 5, 2016
HIV-1 Virus. Credit: J Roberto Trujillo/Wikipedia

Scientists at The Scripps Research Institute (TSRI) and collaborating institutions have described the first-ever immature or "teenage" antibody found in a powerful class of immune molecules effective against HIV.

"This is actually the first example of how we can go back to the really early stage to see how this antibody lineage was born and can develop," said TSRI biologist Jiang Zhu, who served as co-senior author of the study.

The research was an international collaboration, also led by Yuxing Li of the University of Maryland, Yiming Shao of the Chinese Center for Disease Control and Prevention (China CDC), Peking University and Nankai University and Ian Wilson of TSRI.

The new knowledge of the evolution and key traits of anti-HIV antibodies could help researchers design a vaccine to prevent AIDS.

The study, published April 5, 2016, online ahead of print, will be featured as the cover story of the journal Immunity.

Targeting the Virus

HIV has been hard to beat because the virus mutates rapidly and has a sturdy set of defenses—including a "shield" of glycan molecules on the surface of its envelope glycoproteins. These glycoproteins are the viral machinery used to make initial contact and subsequently infect human host cells.

Because HIV presents such a challenge to the immune system, scientists can't use traditional methods to create a vaccine. Instead, Zhu explained, they have to "reverse engineer" the right vaccine candidates using rare effective antibodies from HIV-positive patients as guides.

The antibody in the new study came from a patient in China who was what scientists call an "elite" controller, meaning the patient's immune system had managed to create antibodies with some ability to fight the disease. The patient was among the top 5 percent of neutralizers assessed in a screening of hundreds of Chinese HIV patients by China CDC scientists.

Genetically, the antibody found in this donor resembled members of the VRC01 class of antibodies, which are "broadly neutralizing antibodies," named for their ability to target a key site of vulnerability on many strains of the virus.

Yet the new antibody also lacked one of the key structural traits of VRC01 antibodies. "There was something a little bit weird about this antibody," said Zhu.

Further studies into the antibody's genetics and structure showed that it was a precursor to mature VRC01 antibodies—in other words, it represented a middle stage in the evolution of this class of HIV killers.

Zhu called the antibody a "teenager" and said it gives scientists a unique view of the steps needed to prompt the to effectively target HIV.

Guiding Antibody Development

The researchers studied samples taken from the patient over five years, starting in 2006 when Zhu said the antibody was a "toddler." Each sample showed the antibody in a different stage of development, giving researchers a possible guide for how to elicit these antibodies with a vaccine.

Zhu and his colleagues were surprised to find that the antibody evolved rapidly between 2006 and 2008, gaining many of the traits it would need to fight HIV. This finding contradicts previous studies suggesting that it can take up to 10 to 15 years for VRC01 antibodies to develop useful traits.

"That was a solid theory—until we saw the antibody from this donor," said Zhu.

"Now we know these specialized antibodies can evolve in just one or two years," added TSRI Research Associate Yajing Chen, who served as co-first author of the study with Leopold Kong (formerly of TSRI, now at NIH), TSRI Staff Scientist Linling He, and Bin Ju, Jiandong Liu and Li Ren of the China CDC.

Zhu said this discovery is encouraging, since an HIV vaccine will also need to prompt the body to make antibodies quickly.

The scientists also spotted a hurdle they will have to overcome as they engineer their own : The teenage VRC01 has a slightly longer amino acid chain at one site than the mature version, and this chain clashes with part of the glycoprotein shield (gp120) on HIV and prevents the antibody from effectively neutralizing the virus.

The researchers managed to tweak the immature antibody to make it into a broadly neutralizing antibody. "As long as you have some of those VRC01 signatures, a teenage-stage antibody can become a killer for HIV," said Zhu.

The researchers also noted that this is the first time a VRC01-like antibody has been isolated from a patient of Asian descent—the other VRC01s had come from African or Caucasian patients. This means people with different genetic backgrounds may benefit from a vaccine that harnesses a person's ability to make VRC01s.

"This could be important for developing a universal HIV vaccine," Zhu said.

Explore further: Findings in humans provide encouraging foundation for upcoming AIDS vaccine clinical trial

More information: "Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies within an HIV-1-infected Chinese donor," Immunity, 2016.

Related Stories

Findings in humans provide encouraging foundation for upcoming AIDS vaccine clinical trial

March 24, 2016
Some people infected with HIV naturally produce antibodies that effectively neutralize many strains of the rapidly mutating virus, and scientists are working to develop a vaccine capable of inducing such "broadly neutralizing" ...

Researchers unravel pathways of potent antibodies that fight HIV infection

March 3, 2016
One of the most crucial and elusive goals of an effective HIV vaccine is to stimulate antibodies that can attack the virus even as it relentlessly mutates.

HIV antibody infusion safely suppresses virus in infected people

December 23, 2015
A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in ...

Scientists find surprising trait in anti-HIV antibodies

November 17, 2015
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.

New TSRI study shows HIV structure in unprecedented detail

March 3, 2016
A new study from scientists at The Scripps Research Institute (TSRI) describes the high-resolution structure of the HIV protein responsible for recognition and infection of host cells.

Scientists engineer vaginal lactobacillus to express neutralizing HIV-1 antibody fragments

March 24, 2016
A normal, predominant bacterial species of the healthy vaginal microbiota can be engineered for potential use as a novel protective agent against HIV-1 transmission in women, according to a new publication from scientists ...

Recommended for you

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

National roll-out of PrEP HIV prevention drug would be cost-effective

October 18, 2017
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, ...

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.